Celgene (NASDAQ:CELG) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday. The firm presently has a $114.80 target price on the biopharmaceutical company’s stock. Vetr‘s price target points to a potential upside of 12.53% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a report on Tuesday, September 26th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a report on Thursday, September 21st. Royal Bank of Canada reiterated a “buy” rating and set a $173.00 price target on shares of Celgene in a report on Thursday, October 5th. JPMorgan Chase & Co. restated a “buy” rating on shares of Celgene in a research note on Monday, October 16th. Finally, Jefferies Group restated a “buy” rating and issued a $160.00 target price on shares of Celgene in a research note on Monday, October 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene presently has a consensus rating of “Buy” and an average target price of $130.95.

Shares of Celgene (CELG) traded down $2.80 during trading hours on Wednesday, reaching $102.02. 11,870,000 shares of the company traded hands, compared to its average volume of 6,290,000. The company has a market cap of $80,320.00, a P/E ratio of 24.06, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. Celgene has a one year low of $94.55 and a one year high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.58 EPS. analysts predict that Celgene will post 6.69 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in CELG. Jennison Associates lifted its position in Celgene by 28.3% during the third quarter. Jennison Associates now owns 12,365,141 shares of the biopharmaceutical company’s stock valued at $1,337,537,000 after acquiring an additional 2,728,714 shares during the last quarter. Gerstein Fisher raised its holdings in shares of Celgene by 1.5% in the third quarter. Gerstein Fisher now owns 62,674 shares of the biopharmaceutical company’s stock worth $6,779,000 after buying an additional 941 shares during the last quarter. J. Goldman & Company purchased a new position in shares of Celgene in the third quarter worth $0. Eagle Asset Management raised its holdings in shares of Celgene by 83.7% in the third quarter. Eagle Asset Management now owns 78,876 shares of the biopharmaceutical company’s stock worth $8,532,000 after buying an additional 35,935 shares during the last quarter. Finally, Chelsea Counsel Company raised its holdings in shares of Celgene by 2.3% in the third quarter. Chelsea Counsel Company now owns 4,400 shares of the biopharmaceutical company’s stock worth $476,000 after buying an additional 100 shares during the last quarter. 79.85% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/17/celgene-celg-raised-to-strong-buy-at-vetr.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.